NCT00192283已完成3 期
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) in Healthy Children Attending Day Care Centers
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 2,903
- 试验地点
- 2
- 主要终点
- The primary endpoint for efficacy is the first episode in a study child of a cultureconfirmed influenza illness.
研究概览
简要总结
The purpose of this study is to determine the efficacy of the liquid formulation of CAIVT against culture confirmed influenza illness in healthy children aged at least 6 months and less than 36 months, attending day care centers in Europe. In addition, the trial provides the opportunity to investigate the effect of CAIV-T on acute otitis media, on healthcare resource utilization and economic resources.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- Double
入排标准
- 年龄范围
- 6 Months 至 36 Months（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •who are aged at least 6 months and less than 36 months of age at the time of enrollment, attending day care for at least three days a week, four hours a day;
- •who are in good health as determined by medical history, physical examination and clinical judgement;
- •whose parent(s)/legal guardian(s) have provided written informed consent after the nature of the study has been explained;
- •who, along with their parent(s)/legal guardian(s), will be available for duration of the trial (8 months ± 1 month);
- •whose parent(s)/legal guardian(s), can be reached by study staff for the post-vaccination contacts [telephone, clinic or home visit].
排除标准
- •whose parent(s)/legal guardian(s) are perceived to be unavailable or difficult to contact for evaluation or study visits during the study period;
- •with any serious chronic disease (e.g., with signs of cardiac or renal failure or severe malnutrition), including progressive neurological disease;
- •with Down's syndrome or other known cytogenetic disorders;
- •with a known or suspected disease of the immune system or those receiving immunosuppressive therapy, including systemic corticosteroids; who received any blood products, including immunoglobulin, in the period from six months prior to vaccination through to the conclusion of the study;
- •for whom there is intent to administer any other investigational vaccine or agent from one month prior to enrollment through to the conclusion of the study;
- •have an immunosuppressed or an immunocompromised individual living in the same household; who, at any time prior to entry into this study, received a dose of any influenza vaccine (commercial or investigational);
- •who, in the two weeks prior to entry into this study, received a dose of any influenza treatment (commercial or investigational);
- •with a documented history of hypersensitivity to egg or egg protein or any other component of the study vaccine or placebo;
- •with a clinically confirmed respiratory illness with wheezing within two weeks prior to enrollment;
- •who received aspirin (acetylsalicylic acid) or aspirin-containing products in the two weeks prior to enrollment or for which use is anticipated during the study;
- •who were administered any live virus vaccine within one month prior to enrollment or expected to receive another live virus vaccine within one month of vaccination in this study;
- •with any medical conditions that in the opinion of the investigator might interfere with interpretation of the study results; If any of these criteria are met following enrolment, the subject will be excluded from subsequent vaccine dosing.
- •Note: A pregnant household member is not considered a contraindication to enrollment.
结局指标
主要结局
The primary endpoint for efficacy is the first episode in a study child of a cultureconfirmed influenza illness.
时间窗: 28 days after vaccination
次要结局
- The secondary endpoint for culture-confirmed influenza illness is the first episode caused by any community-acquired antigenic subtype which occurs following receipt of the second dose of study vaccine or placebo.(28 days after vaccination)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Trial to Assess the Safety and Tolerability of the Liquid Formulation of CAIV-T in Healthy Children.HealthyNCT00192400MedImmune LLC2,160
已完成
1 期
Phase I Trial Evaluating Safety and Tolerability of CAIV-T in Healthy Japanese Male AdultsHealthy Japanese Male AdultsNCT00224783MedImmune LLC45
已完成
3 期
Trial to Compare the Safety,Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus Vaccine, Trivalent, Inactivated (TIV) in ChildrenRespiratory Tract InfectionsNCT00192205MedImmune LLC2,200
Unknown
2 期
Topical Ionic Contra-Viral Therapy in Actinic KeratosisActinic KeratosisNCT03684772Maruho Co., Ltd.32
已完成
3 期
Trial To Assess Safety And Efficacy Of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) In Adults Aged 60 Years And OlderInfluenzaNCT00217230MedImmune LLC3,000